The Ledger

Merck KGaA agreed Monday to pay $1.3 billion in cash for Silence Therapeutics, a 130% premium for a company whose lead drug has only Phase 2 data. Merck KGaA, the German group (not the U.S. drugmaker Merck & Co.), will pay $20.00 per American Depositary Share (ADS) for Silence, a U.K.-based developer of small interfering RNA (siRNA) medicines, per the Silence 8-K and press release. The equity value is about $1.3 billion and the enterprise value $1.1 billion. The price is 82% above the 30-day volume-weighted average of $10.99. Silence’s lead candidate, divesiran, targets polycythemia vera (PV), a rare blood cancer, and holds FDA Fast Track and Orphan Drug designations. The deal runs through a U.K. scheme of arrangement, needs shareholder and court approval, and is expected to close in the first quarter of 2027. Holders of about 14% of the voting power have signed support agreements, and the interim chair said the price came out of a competitive sale process. Who it hits: hematology and oncology providers only if divesiran reaches the market, which is years away. The nearer-term read is for buyers of rare-disease assets, where a Phase 2 readout can now command a triple-digit premium. Confidence: High on terms (primary filing); Low on what the drug will earn.

The Federal Trade Commission (FTC) sent both MiMedx and Sanara MedTech a Second Request on October 15, which puts MiMedx’s $350 million purchase of Sanara on a longer clock. A Second Request is a demand for additional documents and data in an antitrust review. Per the MiMedx 8-K filed October 16, the waiting period under the Hart-Scott-Rodino Act now runs until 30 days after both companies substantially comply, unless the parties extend it or the FTC ends it early. The filing gives no new closing date. At signing on July 29, MiMedx offered Sanara holders $33.00 in cash plus 0.4735 MiMedx shares per share, about $35, for an enterprise value near $350 million, with a $300 million term loan from Hayfin Capital Management funding the cash, and targeted a close by year-end, per MassDevice (supplemental; we did not retrieve the July filing). Who it hits: hospitals and surgical centers that buy regenerative and wound-care products from either company, and any buyer weighing a deal in a niche where the FTC will now read the documents. Our read, registered on the public ledger: the deal does not close by December 31. Confidence: High on the Second Request; Med on the timing call.

Suki, an artificial intelligence (AI) company that sells voice-driven documentation assistants to clinicians, raised a $90 million Series E on October 13 to build agents that handle referrals, scheduling and prior authorization. Coverage by Healthcare Dive and Fierce Healthcare names Healthier Capital, Crosslink Capital and Hercules Capital as new investors, with Venrock, Flare Capital Partners and others returning. Suki says it has raised more than $250 million in total and did not disclose a valuation. The customer count differs by outlet, more than 450 organizations in some reports and more than 250 in Fierce’s, and a $60 million to $80 million 2026 revenue projection traces to a single unconfirmed report, so we repeat neither as fact. Who it hits: health systems paying for scribe tools that are now being pitched as back-office automation, and competing ambient documentation vendors. We could not open the company’s release, so this rests on trade reporting. Confidence: High on the round size; Low on customer count and revenue.

Elevance Health reports third-quarter results Wednesday, and the bar is UnitedHealth’s 88.4% medical care ratio. UnitedHealth’s October 13 8-K showed a medical care ratio (the share of premiums spent on care) of 88.4%, against 89.9% a year earlier, but that included $610 million of favorable prior-period reserve development. The same filing showed UnitedHealthcare medical membership of 48.3 million, down from 50.1 million, and Medicare Advantage membership of 7.6 million, down from 8.4 million. So what: an insurer can improve its ratio by shedding members and repricing, which is the pattern hospitals and physician groups feel as narrower networks and lost volume. Elevance’s release is scheduled for 6:00 a.m. Eastern with a call at 8:30 a.m. on October 21, per a news aggregator’s copy of the company notice that we could not confirm on its investor site. Watch its ratio ex-reserve releases, Medicaid cost trend and ACA exchange membership. Confidence: High on UnitedHealth figures; Med on the Elevance date.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Silence Therapeutics	Merck KGaA, Darmstadt, Germany	Biotech, siRNA medicines	$1.3 billion equity, $1.1 billion enterprise; close expected Q1 2027	Silence 8-K
Sanara MedTech (pending, FTC Second Request October 15)	MiMedx Group	Regenerative and wound-care products	About $350 million enterprise value (announced July 29)	MiMedx 8-K
Suki (Series E, announced October 13)	Healthier Capital, Crosslink Capital, Hercules Capital, existing investors	Health AI, clinical documentation and agents	$90 million	Healthcare Dive, supplemental

Scan covered SEC 8-K filings dated October 16 to 19, company releases and trade press. No health system, private equity platform or bankruptcy transaction beyond these was confirmed from a primary source in the last 24 hours.